The bull market continues; markets quickly dusted off the 5% correction in April and soared to new highs. With too much cash on the sidelines, every shallow correction has become a buying opportunity. Blue-chip stocks are one way to play this positive momentum.From a historical perspective, the markets are in great shape for continued gains. In the first 100 trading days of 2024, the S&P 500 has had about a 10% gain. JPMorgan Wealth Management noted that since 1950, that has meant a stronger second half, wi ...

Abbott (ABT) closed at $103.95 in the latest trading session, marking a -0.27% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.7%. At the same time, the Dow added 0.01%, and the tech-heavy Nasdaq gained 1.1%.Shares of the maker of infant formula, medical devices and drugs witnessed a loss of 2.46% over the previous month, trailing the performance of the Medical sector with its gain of 3.27% and the S&P 500's gain of 4.03%.Analysts and investors alike will be keepin ...

Abbott Laboratories (ABT) is well-poised to grow in the coming quarters, backed by its Nutrition business, which continues to recover shares and grow its Adult business. Within Diabetes care, Libre’s solid sales trajectory is encouraging and should continue to sustain with several new growth opportunities. Strong potential in the Diagnostics space is highly promising as well.However, the company faces challenges from lower demand for COVID-19 testing, which is hurting growth, as well as adverse currency mov ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT) .Abbott currently has an average brokerage recommendation (ABR) of 1.53, on a scal ...

PALM BEACH, Fla., May 21, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The sports nutrition market is experiencing significant growth due to the evolving preferences of consumers seeking healthier and tailored nutritional options and for maintaining muscle growth during weight loss. The sports nutrition market is experiencing robust growth due to increasing consumer awareness about the importance of fitness and healthy lifestyles. Industry players are emphasizing innovation in product developme ...

A team of scientists work in a laboratory. AzmanL/E+ via Getty Images For my money, the name of the game in dividend growth investing is to buy best-of-breed companies operating in industries with favorable growth tailwinds. That's because this can help a company deliver the sales and profit growth that is necessary to support a rising payout to shareholders. Well, few growth trends are as powerful as healthcare. As medical treatments advance, the world ages, and grows in population/wealth, the demand cur ...

These two healthcare stocks are well-known for their top-tier dividend programs.Dividend stocks tend to struggle in high-interest-rate environments. The core reason is investors have an abundance of low-risk, high-yield income options when interest rates spike.Conversely, fund managers have historically pivoted to top-tier dividend stocks when interest rates fall. The logic behind this trend is that dividend stocks ought to deliver superior returns to risk-free assets like U.S. T-bills in low-rate environme ...

文章核心观点 - 摩根大通在5月推荐了5只蓝筹股作为被动收入的首选标的 这些公司具有稳定的总回报潜力和可靠的分红 适合寻求被动收入的投资者 [2] - 这些股票来自不同行业 包括金融、医疗、消费品和工业等领域 其中两家公司是巴菲特的重仓股 [2] - 与高估值的AI股票相比 这些蓝筹股更具稳定性 在当前市场环境下更具吸引力 [2] 摩根大通推荐股票分析 摩根大通公司(JPM) - 华尔街和全球投资领域的公认领导者 研究部门持续为客户提供最佳投资建议 [5] - 所有推荐股票均被摩根大通评为"增持"评级 [5] 雅培实验室(ABT) - 全球领先的医疗保健公司 业务涵盖制药、诊断、营养品和医疗设备四大领域 [7] - 提供多种治疗药物 包括胰腺外分泌功能不全、肠易激综合征、高血压等疾病的治疗药物 [7] - 诊断产品包括实验室和输血医学系统、分子诊断仪器、远程患者监测系统等 [7] - 提供2.05%的股息收益率 [7] 美国银行(BAC) - 美国领先的金融机构 在美国运营5100个银行中心和16300台ATM [9] - 第一季度业绩超出分析师预期 提供2.81%的股息收益率 [9] - 巴菲特持有13%的流通股 占伯克希尔投资组合的9.5% [9] 可口可乐(KO) - 全球最大饮料公司 拥有500多个品牌 包括20个价值超过10亿美元的品牌 [12] - 每日全球消费量超过19亿份 在200多个国家销售 [12] - 巴菲特持有4亿股 提供3.22%的股息收益率 [12] - 持有怪兽饮料16.7%的股份 [12] 霍尼韦尔国际(HON) - 全球领先的工业公司 业务涵盖航空航天技术、楼宇自动化、能源解决方案和工业自动化 [15] - 如果全球经济复苏 该公司有望在2024年表现良好 [15] - 提供2.20%的股息收益率 [15] 默克公司(MRK) - 全球领先的医疗保健公司 业务分为制药和动物健康两大板块 [18] - 制药业务涵盖肿瘤学、免疫学、神经科学、病毒学等多个治疗领域 [18] - 提供2.83%的股息收益率 [18]

Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack of demand per se.Healthcare stocks, especially well-known ones, are no-brainer investments for traders. Their potential is high, and over the long term, their returns are multiplefold.With this in mind, Finbold picked out three healthcare stocks for investors to purchase and hold forever. Johnson & Johnson (NYSE ...

净销售额增长情况 - 2024年第一季度，Abbott的总净销售额增长了5.1%，不考虑外汇影响[65] - 2024年第一季度，除了COVID-19测试相关销售的影响，Abbott的总净销售额增长了8.2%[65] - 2024年第一季度，除了COVID-19测试相关销售和外汇影响，Abbott的总净销售额增长了11.3%[65] 各部门销售情况 - 2024年第一季度，医疗器械和成熟制药产品部门的销售额增长较快，而COVID-19快速诊断试剂销售需求下降[65] - 2024年第一季度，Established Pharmaceutical Products的关键新兴市场销售额增长了15.4%[67] - 2024年第一季度，Nutritional Products的总销售额增长了7.7%[68] - 2024年第一季度，Diagnostic Products的销售额下降了15.5%，主要受COVID-19测试需求下降影响[70] - 2024年第一季度，Medical Devices的总销售额增长了15.4%[73] - 2024年第一季度，FreeStyle Libre销售额同比增长23.3%[74] 财务状况 - Abbott在2024年第一季度的现金及现金等价物从2023年12月底的69亿美元减少到2024年3月底的63亿美元，主要反映了支付股息和资本支出，部分抵消了2024年前三个月运营活动所产生的现金[92] - Abbott在2024年第一季度的经营活动净现金约为10亿美元，较去年同期减少1.18亿美元，主要反映了2024年运营收入下降和应收账款增加[93] - Abbott在2024年第一季度宣布每股普通股派息0.55美元，较2023年第一季度宣布的0.51美元每股派息增长了7.8%[96] 新产品与合作 - 2024年第一季度，Abbott宣布与Tandem Diabetes Care和Insulet合作推出新的胰岛素泵产品[75]